Combination of Henagliflozin and Continuous Subcutaneous Insulin Infusion in T2DM

Summary

The Multi-center, randomized, controlled clinical trial investigate the efficacy and safety of Henagliflozin combined with continuous subcutaneous insulin infusion in newly diagnosed type 2 diabetes

Timeline

Start

2023-03-01

Primary completion

2024-10-30

Completion

2024-10-30

Outcome

Met primary endpoint

paper The TIR was significantly greater in the henagliflozin+CSII group than in the CSII group (79.85% vs. 74.06%; p = 0.005). PMID 41853855 ↗

Publications

• Huang Z, Wu Y, Tang C, Yao B, Xie X, Bin X, Yan X, Deng T, Yang W, Chen G, Zhang Y, Wei W, Yang B, Peng T, Zhuo L, Li Y, He Y, Ma S, Qin Y. A Multicentre, Randomised, Controlled, Open-Label Study of Continuous Subcutaneous Insulin Infusion Plus Henagliflozin for Treating Type 2 Diabetes Mellitus Patients With Severe Hyperglycaemia. Diabetes Obes Metab. 2026 Jun;28(6):4806-4817. doi: 10.1111/dom.70665. Epub 2026 Mar 19.
• Wu Y, Huang Z, Qin Y. Efficacy and safety of henagliflozin combined with continuous subcutaneous insulin infusion in the treatment of Chinese inpatients with type 2 diabetes mellitus based on a continuous glucose monitoring system: protocol of a multicentre, open-label, inpatient, randomised, controlled trial. BMJ Open. 2024 Oct 11;14(10):e084834. doi: 10.1136/bmjopen-2024-084834.

Drugs

Indications